87 related articles for article (PubMed ID: 24896838)
21. Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements.
Lin CJ; Wason JMS
Stat Med; 2017 Dec; 36(29):4616-4626. PubMed ID: 28850689
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase II selection design with order constrained strata.
Chen Y; Yu M
Biometrics; 2024 Jan; 80(1):. PubMed ID: 38364810
[TBL] [Abstract][Full Text] [Related]
23. Statistical considerations in model-based dose finding for binary responses under model uncertainty.
Yan Z; Yang M
Stat Med; 2024 May; 43(12):2472-2485. PubMed ID: 38605556
[TBL] [Abstract][Full Text] [Related]
24. A Bayesian adaptive biomarker stratified phase II randomized clinical trial design for radiotherapies with competing risk survival outcomes.
Park J; Hu W; Jin IH; Liu H; Zang Y
Stat Methods Med Res; 2024 Jan; 33(1):80-95. PubMed ID: 38062757
[TBL] [Abstract][Full Text] [Related]
25. A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies.
Dufault SM; Crook AM; Rolfe K; Phillips PPJ
Stat Med; 2024 Feb; 43(3):501-513. PubMed ID: 38038137
[TBL] [Abstract][Full Text] [Related]
26. Sufficient trial size to inform clinical practice.
Manski CF; Tetenov A
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10518-23. PubMed ID: 27601679
[TBL] [Abstract][Full Text] [Related]
27. A unified Bayesian framework for bias adjustment in multiple comparisons from clinical trials.
Du Y; Li J; Raha S; Qu Y
Stat Med; 2024 Jul; 43(15):2928-2943. PubMed ID: 38742595
[TBL] [Abstract][Full Text] [Related]
28. Bayesian variable selection based on clinical relevance weights in small sample studies-Application to colon cancer.
Boulet S; Ursino M; Thall P; Jannot AS; Zohar S
Stat Med; 2019 May; 38(12):2228-2247. PubMed ID: 30672015
[TBL] [Abstract][Full Text] [Related]
29. Clinical trials: subgroup analyses in randomized trials--more rigour needed.
Altman DG
Nat Rev Clin Oncol; 2015 Sep; 12(9):506-7. PubMed ID: 26215043
[No Abstract] [Full Text] [Related]
30. Single-arm Phase II cancer survival trial designs.
Wu J
J Biopharm Stat; 2016; 26(4):644-56. PubMed ID: 26098141
[TBL] [Abstract][Full Text] [Related]
31. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
[TBL] [Abstract][Full Text] [Related]
32. Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021.
Agrawal S; Arora S; Amiri-Kordestani L; de Claro RA; Fashoyin-Aje L; Gormley N; Kim T; Lemery S; Mehta GU; Scott EC; Singh H; Tang S; Theoret MR; Pazdur R; Kluetz PG; Beaver JA
JAMA Oncol; 2023 Feb; 9(2):266-272. PubMed ID: 36580315
[TBL] [Abstract][Full Text] [Related]
33. Feasibility of implementing a novel behavioural smoking cessation intervention amongst human immunodeficiency virus-infected smokers in a resource-limited setting: A single-arm pilot trial.
Tsima BM; Moedi P; Maunge J; Machangane K; Kgogwane M; Mudojwa T; Bastian J; Bilker W; Ashare R; Schnoll R; Gross R
South Afr J HIV Med; 2020; 21(1):1075. PubMed ID: 32670627
[TBL] [Abstract][Full Text] [Related]
34. Optimizing the study design of clinical trials to identify the efficacy of artificial intelligence tools in clinical practices-Authors' reply.
Li R; Zhao L; Yun D; Lin H
EClinicalMedicine; 2019 Nov; 16():12-13. PubMed ID: 31832611
[No Abstract] [Full Text] [Related]
35. A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.
Grayling MJ; Dimairo M; Mander AP; Jaki TF
J Natl Cancer Inst; 2019 Dec; 111(12):1255-1262. PubMed ID: 31218346
[TBL] [Abstract][Full Text] [Related]
36. Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data.
Ventz S; Lai A; Cloughesy TF; Wen PY; Trippa L; Alexander BM
Clin Cancer Res; 2019 Aug; 25(16):4993-5001. PubMed ID: 31175098
[TBL] [Abstract][Full Text] [Related]
37. To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.
Vanderbeek AM; Ventz S; Rahman R; Fell G; Cloughesy TF; Wen PY; Trippa L; Alexander BM
Neuro Oncol; 2019 Oct; 21(10):1239-1249. PubMed ID: 31155679
[TBL] [Abstract][Full Text] [Related]
38. Do single-arm trials have a role in drug development plans incorporating randomised trials?
Grayling MJ; Mander AP
Pharm Stat; 2016; 15(2):143-51. PubMed ID: 26609689
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
